Elanco Animal Health Incorporated ELAN

ELAN Company Overview

Elanco Animal Health Incorporated is a global animal health company focused on developing, manufacturing, and marketing products for companion animals and livestock. The company operates within the broader animal health and veterinary pharmaceutical industries, with revenue primarily generated through pet health therapeutics, parasiticides, vaccines, medicated feed additives, and productivity products for cattle, poultry, swine, and aquaculture markets. Elanco serves veterinarians, livestock producers, retailers, distributors, and pet owners across developed and emerging markets. The company’s portfolio includes products addressing flea and tick control, pain management, dermatology, vaccines, digestive health, and food animal productivity.

Elanco was originally established as the animal health division of Eli Lilly and Company before being separated through an initial public offering in 2018 and fully spun off in 2019. The company significantly expanded its scale through the acquisition of Bayer Animal Health in 2020, which strengthened its companion animal portfolio and broadened its international presence. Elanco’s strategic positioning is built around a diversified product base spanning both pet health and farm animal health, extensive veterinary relationships, and global distribution capabilities.